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ABSTRACT
Introduction: Renal cell carcinoma (RCC) is the most
common neoplasm in adult kidneys. One of the most
important unmet medical needs in RCC is a prognostic
biomarker to enable identification of patients at high
risk of relapse after nephrectomy. New biomarkers can
help improve diagnosis and hence the management of
patients with renal cancer. Thus, this systematic review
aims to clarify the prognostic and diagnostic accuracy
of miR-21 in patients with RCC.
Methods and analysis: We will include
observational studies evaluating the diagnostic and
prognostic roles of miR-21 in patients with renal
cancer. The index test and reference standards should
ideally be performed on all patients. We will search
PubMed, SCOPUS and ISI Web of Science with no
restriction of language. The outcome will be survival
measures in adult patients with RCC. Study selection
and data extraction will be performed by two
independent reviewers. QUADAS-1 will be used to
assess study quality. Publication bias and data
synthesis will be assessed by funnel plots and Begg’s
and Egger’s tests using Stata software V.11.1.
Ethics and dissemination: No ethical issues are
predicted. These findings will be published in a peer-
reviewed journal and presented at national and
international conferences.
Trail registration number: This systematic review
protocol is registered in the PROSPERO International
Prospective Register of Systematic Reviews,
registration number CRD42015025001.
INTRODUCTION
Renal cell carcinoma (RCC) is the most
common neoplasm in adult kidneys.1 The
incidence of RCC is increasing by approxi-
mately 20% per annum.2 Distinguishing the
RCC subtypes is of clinical importance
because they have different prognoses and
subsequently require different management
plans.3 The most common form of RCC is
the clear subtype RCC (ccRCC) that
accounts for 75%–80% of cases; other less
common subtypes include papillary RCC
(pRCC), chromophobe RCC (chRCC) and
collecting duct carcinoma.4 Although
surgery is curative for the localised disease, a
significant proportion of patients relapse or
metastasise. Metastatic RCC is difficult to
treat. The 5-year survival rate for metastatic
RCC is dismal at less than 10%.5 At present,
there is an absence of biomarkers for the
early detection and follow-up of the disease,
which is responsible for the late diagnosis
and the subsequent poor prognosis.6
Factors influencing RCC prognosis can be
classified into anatomic, histological, clinical
and molecular.2 Pathological stage, based on
the size and extent of invasion by the
tumour, is the most accurate indicator of
prognosis.7 Recent evidence shows that
molecular signatures can classify RCC sub-
types more accurately than morphological
characteristics.8–10 Micro RNAs (miRNAs)
are small non-coding RNA nucleotides that
post-transcriptionally regulate the expression
of their target proteins.4 The first report sug-
gesting a role of miRNAs in cancer was pub-
lished in 2002.11
miRNAs are actively involved in kidney
cancer pathogenesis.12 13 Recently, the clin-
ical implications of miRNAs in RCC have
been systematically reviewed;14 moreover, the
potential roles of miRNAs as prognostic and
Strengths and limitations of this study
▪ This systematic review, for the first time, will
evaluate the prognostic and diagnostic accuracy
of miR-21 in patients with renal cell carcinoma
through a search of several databases without
placing restrictions on language.
▪ The study screening, data extraction and assess-
ment of risk of bias of the current study will be
conducted by two researchers independently.
▪ We expect some potential heterogeneities
between previous studies, including stage and
histological grade in patient samples.
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diagnostic tools in RCC as well as its subtypes have been
reported in several studies.4 15–34
Among the numerous miRNAs, miR-21 has received
specific attention because of its relationship with mul-
tiple cancers. It is upregulated in several tumours,
including cancers of the breast, lung, colon, pancreas,
prostate and stomach.35–38 The effect of miR-21 on
carcinogenesis and tumour progression has been
experimentally analysed.39 miR-21 regulates epithelial–
mesenchymal transition phenotype and hypoxia-
inducible factor-1α expression in breast cancer stem
cell-like cells and contributes to cell migration in metas-
tasis.40 The global prediction role of miR-21 for survival
in patients with various carcinomas has been sum-
marised in a meta-analysis.41
To date, several researchers have published their data
on the prognostic value of miR-21 in RCC and raised
concerns about its prognostic accuracy as a biomarker;
however, these issues remain questionable.4 17 19 31 This
systematic review aims to evaluate the diagnostic and
prognostic accuracy of miR-21 in patients with RCC.
OBJECTIVES
The primary objectives are to determine the diagnostic
and prognostic accuracy of miR-21 in patients with RCC.
The secondary objectives include determining the diag-
nostic and prognostic accuracy of miR-21 in RCC sub-
types together with the evaluation of heterogeneity and
its potential sources in primary studies.
METHODS
The methods adopted for this systematic review have
been developed in accordance with the guidelines
detailed on the PRISMA checklist. In addition, the
PRISMA Flow Diagram will be employed to describe the
flow of information through the different phases of this
systematic review.42 The protocol of this systematic review
has been registered in PROSPERO 2015 (registration
number: CRD42015025001). The Preferred Reporting
Items for Systematic reviews and Meta-Analyses for
Protocols 2015 (PRISMA-P 2015) have been used for
preparing and reporting the protocol of this systematic
review.43
INCLUSION CRITERIA
Types of studies
Observational studies (cross-sectional, case–control and
cohort) will be included. Studies assessing animal
models, review articles, proceedings, conferences and
case series on patients dead from RCC will be excluded.
Participants
Adult patients of both sexes with a diagnosis of RCC will
be included. Tumour classification and stage will be
diagnosed according to the TNM system and 2004 WHO
classification.44 45
Index test
miR-21
miRNAs are highly conserved small non-coding RNA
strands, approximately 22 nucleotides in length, that
post-transcriptionally regulate gene expression and
appear to be modulators of urological cancers.46 47
miR-21 is one of the most frequently studied cancer-
related miRNAs and is dysregulated in most cancers by
acting as an oncogene.48
RCC considerably exploits the upregulation of miR-21
in comparison with healthy kidneys.4 39 A significant dif-
ference exists between the expression levels of
miR-21and RCC subtypes with respect to the highest
levels in ccRCC and pRCC subtypes. miR-21 levels are
associated with higher stage and grade, and hence its
expression level can be used as a diagnostic marker in
distinguishing RCC subtypes.4 The expression level of
miR-21 is correlated with a span of 5-year survival and
pathological stage in RCC.49 Patients who are miR-21
positive have statistically shorter disease-free survival
(DFS) and overall survival (OS) rates.4 In the current
review, miR-21 detection in RCC tissues will be defined
on the basis of quantitative real-time PCR (qRT-PCR).
There are several steps for miR-21 detection in RCC
tissues based on qRT-PCR, which are as follows:
1. Total RNA is extracted from RCC samples (formalin-
fixed, paraffin-embedded tissues or serum) using
commercial kits, according to the manufacturer’s
protocol.
2. RNA concentrations and A260/280 ratio with a Nano
Drop are determined.
3. The resulting miRNA for qRT-PCR is retained, and
miRNA expression is measured by TaqMan miRNA
assays.
4. Reverse transcription of miR-21 with a specified
amount of total RNA using the TaqMan
MicroRNA-specific Reverse Transcription Kit is
performed.
5. The cycling conditions for miR-21 are selected
according to the manufacturer’s protocols.
6. All reactions are performed in triplicates.
7. The values of miR-21 with respect to a small nuclear
RNA as a reference gene are normalised.
8. The relative overexpression or underexpression of
miR-21 in patient samples is compared to that in
normal subjects by the ΔΔCt method.4 7 19 31
Gold standards
Studies will be eligible for this review if the clinical diag-
nostic criteria recommended by the WHO classification
and TNM system of the renal tumours of adults are used
as primary reference standards. The pathological diag-
nosis of RCC is recommended for all renal masses exist-
ent in radical nephrectomy or biopsies. Since clinical
practice guidelines are routinely updated, we will use the
criteria of reference standard that the primary studies
adopted. Survival measures such as DFS, OS, recurrence-
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free survival (RFS) and HR with 95% CI will be used as
reference standards for prognostic accuracy.
Target conditions
The target conditions for diagnostic and prognostic
values will be verified by RCC diagnosis and survival
measures, respectively.
Outcomes
The primary outcomes will be all survival measures of
patients with RCC. The secondary outcomes will include
the determination of prognostic accuracy of miR-21 in
different subtypes of renal cancer, as well as the deter-
mination of heterogeneity and its potential sources.
SEARCH METHODS FOR IDENTIFICATION OF STUDIES
Electronic searches
We will search the following databases: PubMed, Web of
Science and Scopus, till 31 July 2015.
PubMed search strategy
MeSH tags were found in PubMed. The details of the
PubMed database search strategy and syntax are sequen-
tially provided below.
1. miR21
2. miR-21
3. microRNA-21
4. miRNA-21
5. hsa-mir-21
6. 1 or 2 or 3 or 4 or 5
7. Renal
8. Kidney
9. 7 or 8
10. 6 and 9
[miR21 (tiab) OR microRNA-21(tiab) OR miRNA-21
(tiab) OR hsa-mir-21(tiab) OR miR-21(tiab)] AND
[kidney (tiab) OR renal (tiab)].
Other resources
Reference lists of relevant primary studies, reviews and
key journals will be searched for additional studies.
Data collection and analysis
A data extraction form will be developed, and study data
will be independently assessed and extracted by two
reviewers, AR and RR.
The following data will be extracted from all the
included studies:
1. Study characteristics (author, year of publication,
study design, setting, locations and patient enrolment
strategies).
2. Test characteristics (test type, test condition, prespeci-
fied cut-off values, sampling protocol and criteria for
test positivity).
3. Reference standards (histopathological diagnosis or
criteria of the guideline used).
4. Participants’ characteristics (age, gender, ethnicity,
disease type, tumour sizes and tumour stages).
5. Statistics for meta-analysis, including true positives,
false positives, true negatives , false negatives, sensitiv-
ity, specificity, positive and negative likelihood ratios,
area under the curve (AUC) for diagnostic value, OS,
DFS and RFS for prognostic values.
Unavailable information from included studies will be
sought from authors by email. Any discrepancies will be
resolved by consensus between AR and RR.
Assessment of methodological quality
The methodological quality of primary studies will be
assessed by a revised tool devised for QUADAS-1 quality
assessment.50 The defined questions will be answered as
yes, no or unclear, and the score of each article will be
calculated. Two authors (AR and RR) will initially com-
plete the pilot QUADAS-1 items in three studies. If the
authors do not agree, we will refine the tool, and then
the updated tool will be applied to complete the assess-
ment for all included studies. Disagreements will be
resolved by consensus.
Assessment of heterogeneity
To investigate heterogeneity, we will include the study
design (prospective or retrospective and year of publica-
tion), population characteristics (gender, ethnicity, age,
disease types and stage distribution), test characteristics
(cut-off value, test type and the total number of tests per
screening round) and versions of reference standards as
our study-level variables. We will test these study-level
covariates in the bivariate model in the common thresh-
old or add them to the Rutter and Gatsonis HSROC
model to evaluate the heterogeneity in the test thresh-
old, diagnostic accuracy and the shape of curves. The
likelihood ratio test will be used to determine the statis-
tical significance of the covariates included in the
models.51
Assessment of reporting bias
The publication bias will be assessed by funnel plots (ie,
plots of study results against precision) and Begg’s and
Egger’s tests.
Statistical analysis and data synthesis
Descriptive analysis
All included studies will be overviewed and presented in
two separate tables. The first table will provide details on
the study quality according to the review-specific
QUADAS-1 tool. The other table will include the study
design, participants, test characteristics, results, out-
comes and reference standards. The following test
characteristics will be extracted into 2×2 tables (TP, FP,
TN and FN) for all included studies. Study-specific esti-
mations of sensitivity and specificity with 95% CI will be
displayed in forest plots using Review Manager (V.5.2).
These graphical displays will reveal the variations in
accuracy among the studies and the different types and
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brands of the index test. The collected data about the
outcomes such as DFS, OS, RFS and HR with 95% CI
will be used for calculating the prognostic value of the
index test.
Inferential statistics
All the included studies will be synthesised after a sys-
temic review. Study-specific HR, sensitivity and specificity
estimates will be pooled using a fixed effect model, if no
significant heterogeneity exists; otherwise, a random
effect model will be applied. The extent of heterogen-
eity throughout the studies will be checked using the χ2
test and I2 test; p=0.10 and/or I2 >50%, indicating sig-
nificant heterogeneity. To evaluate the sources of hetero-
geneity, subgroup analysis and meta-regression will be
performed.
The potential for publication bias will be assessed
using funnel plots, Begg’s rank correlation method and
Egger’s weighted regression method. A p value of ≤0.05
will be considered to be statistically significant.
All the mentioned analyses will be performed using
STATA V.11.1 software (StataCorp LP, College Station,
Texas, USA).
Sensitivity analysis
A sensitivity analysis will be conducted to test the impact
of the results with respect to the methodological quality
items rated by the QUADAS-1 tool criteria. We will also
implement sensitivity analyses to explore the impacts of
methodological quality and sample size on the robust-
ness of review conclusions. Meta-analyses will be
repeated after excluding studies with lower methodo-
logical quality and studies with sample sizes much larger
than those of other studies. Sensitivity analyses will be
reported with a summary table, and reviewed conclu-
sions will be interpreted by making comparisons
between the two meta-analyses.
Subgroup analyses
Subgroup analyses will be conducted according to the
region, gender, quality, sample size and cancer subtype.
DISCUSSION
Despite the comprehensive understanding of the
biology of RCC and recent advances in novel thera-
peutic strategies, the lack of molecular biomarkers for
the early detection and classification of RCC and the
poor prognosis for these patients are major complica-
tions. miR-21 is a tumour marker that is upregulated in
RCC and in several tumours. In RCC, miR-21 is involved
in cellular mechanisms such as growth, apoptosis, cell
cycle, invasion and migration of tumour cells.
Our systematic review will clarify the prognostic and
diagnostic accuracy of miR-21 in patients with RCC,
which would allow patients, clinicians and researchers to
determine the diagnostic performance of miR-21 for the
detection of RCC, particularly early stage RCC, and the
potential role of this marker in the prognosis of patients
with RCC. This systematic review will also help policy-
makers and guideline developers in the management of
patients with RCC.
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